We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

600183:SSEShengyi Technology Co., Ltd. Class A Analysis

Data as of 2026-06-18 - not real-time

CN¥183.87

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Shengyi Technology is trading at CNY 183.87, just below its 52‑week high of 191 and comfortably above the 20‑day SMA (≈145), indicating a strong bullish momentum. The MACD is in a bullish crossover (line 20.6 > signal 17.9) while the RSI sits at an extreme 86, signaling that the stock is technically overbought. Volume has been decreasing despite a very high 30‑day volatility of about 70%, and the beta of roughly 1.05 suggests modest systematic risk. On the fundamentals side, the trailing P/E of 114 dwarfs the industry average of 38, and the DCF‑derived fair value of roughly 19 is a fraction of the current price, pointing to severe overvaluation. Revenue is expanding rapidly at 45% YoY and margins are solid, yet the company carries a high debt‑to‑equity ratio (≈25) and a modest dividend yield of 0.67% with a 61% payout, raising questions about dividend sustainability. Cash generation remains healthy, with operating cash flow exceeding 5.5 billion CNY and free cash flow above 1.3 billion CNY, supporting the business despite leverage. Overall, the stock’s technical setup is bullish but its valuation is stretched, and the high volatility and leverage add to the risk profile.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • RSI in overbought territory
  • Price near resistance at 191
  • Decreasing volume and high short‑term volatility

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong revenue growth and margins
  • Persistently high valuation multiples
  • Elevated debt level limiting upside

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Robust cash flow generation
  • Expanding exposure to AI, 5G, and automotive electronics
  • Potential price correction toward intrinsic value

Key Metrics & Analysis

Financial Health

Revenue Growth45.10%
Profit Margin12.69%
P/E Ratio114.2
ROE24.44%
ROA9.72%
Debt/Equity25.73
P/B Ratio24.9
Op. Cash FlowCN¥5.6B
Free Cash FlowCN¥1.3B
Industry P/E38.1

Technical Analysis

TrendBullish
RSI86.4
SupportCN¥102.00
ResistanceCN¥191.00
MA 20CN¥144.95
MA 50CN¥104.63
MA 200CN¥71.66
MACDBullish
VolumeDecreasing
Fear & Greed Index92.05

Valuation

Fair ValueCN¥19.01
GradeOvervalued
TypeBlend
Dividend Yield0.67%

Risk Assessment

Beta1.06
Volatility70.59%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.